Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …

Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat in more
than 5% of hepatocytes in the absence of excessive alcohol consumption and other …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Background Given the unique phenotype of type 2 diabetes in Japanese patients, novel
therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed …

Obesity is a growing epidemic within the USA. Because weight gain is associated with an
increased risk of developing life-threatening comorbidities, such as hypertension or type 2 …

In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …